Discover REGENXBIO's Upcoming Investor Engagements and Vision
REGENXBIO's Participation in Notable Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) has shared exciting news regarding its involvement in a series of prominent investor conferences. These events provide a vital platform for the company to showcase its pioneering advancements in gene therapy and to engage with stakeholders in the biotechnology community.
Upcoming Events and Conferences
Chardan's 9th Annual Genetic Medicines Conference
REGENXBIO plans to take part in Chardan's inaugural genetic medicines conference. This event is scheduled for October 21, where representatives will contribute to comprehensive discussions surrounding gene therapies and their implications in current medical treatments. Two significant panels are included in the agenda:
- "Battleground States for Muscular Dystrophies" at 2:00 p.m. ET.
- "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers" at 2:45 p.m. ET.
This is a fantastic opportunity for REGENXBIO to engage with other leaders in the industry and discuss ongoing innovations in muscular dystrophy treatment.
Guggenheim Securities Annual Healthcare Innovation Conference
Following this, on November 10, REGENXBIO will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. Here, the company will engage in a fireside chat that focuses on the evolving landscape of healthcare innovation, starting at 9:00 a.m. ET.
Stifel 2025 Healthcare Conference
Furthermore, on November 11, REGENXBIO will also feature in the Stifel 2025 Healthcare Conference with another fireside chat at 1:20 p.m. ET. This engagement aims to give insights into REGENXBIO's revolutionary gene therapies and the impact they hold for patients.
Webcast Accessibility and Archiving
For those interested in tuning into these insightful events, live webcasts will be made available on REGENXBIO's Investors section of their website. You can catch the majority of these discussions live, with access to archived replays for about 30 days after the events, allowing for convenient viewing opportunities.
About REGENXBIO Inc.
REGENXBIO has been at the forefront of biotechnology since its establishment in 2009, focusing on leveraging the potential of gene therapy to bring transformative solutions to healthcare challenges. With a robust late-stage pipeline, the company is committed to developing one-time treatments for rare diseases and retinal disorders.
Among its promising therapies are:
- RGX-202 for Duchenne Muscular Dystrophy
- Clemidsogene lanparvovec (RGX-121) for MPS II
- RGX-111 for MPS I, in collaboration with partners such as Nippon Shinyaku
- Surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy, developed in collaboration with AbbVie
Thousands of patients have already benefited from REGENXBIO's AAV platform, reinforcing the need for innovative therapies like ZOLGENSMA from Novartis. The future looks promising as REGENXBIO continues to develop gene therapies that could redefine healthcare delivery for millions.
Contacts
Dana Cormack
Corporate Communications
Investors:
George E. MacDougall
Investor Relations
Frequently Asked Questions
What is REGENXBIO known for?
REGENXBIO is a biotechnology company focused on advancing gene therapy to treat various diseases, using their proprietary AAV platform.
When will REGENXBIO participate in the conferences?
REGENXBIO is set to participate in conferences on October 21, November 10, and November 11, 2025.
How can I access the webcasts of these events?
Live webcasts can be accessed in the Investors section of REGENXBIO's website, with replays available for around 30 days after the events.
What treatments does REGENXBIO offer?
The company offers several gene therapies, including treatments for Duchenne Muscular Dystrophy and mucopolysaccharidoses, among others.
What is the mission of REGENXBIO?
REGENXBIO’s mission is to transform lives through the curative potential of gene therapy.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.